Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-dilated left ventricular cardiomyopathy in patients with chronic Chagas disease and heart failure with reduced left ventricular ejection fraction.

ESC heart failure·2026
Same author

Serum Cytokine Levels and Heart Rate Variability in the Frequency Domain in Patients With Chronic Chagas Heart Disease.

Cureus·2026
Same author

Editorial of "effect of continuous positive airway pressure on ventricular remodelling of patients with combined diabetes mellitus and obstructive sleep apnea: A cross-sectional study follow on randomised clinical trial" to international journal of cardiology.

International journal of cardiology·2025
Same author

Clinical characteristics, predictors of mortality, and outcome in patients with heart failure with mildly reduced ejection fraction secondary to Chagas cardiomyopathy.

International journal of cardiology·2025
Same author

Expression patterns of Galectin-3 and NLRP3 in Chagas reactivation and graft damage in heart transplants.

Transplant immunology·2024
Same author

Interleukin-12 treatment reduces tumor growth and modulates the expression of CASKA and MIR-203 in athymic mice bearing tumors induced by the HGC-27 gastric cancer cell line.

Pathology, research and practice·2024
Same journal

Clinical outcomes of intravascular imaging-guided versus angiography-guided drug-coated balloon angioplasty for de novo coronary lesions.

International journal of cardiology·2026
Same journal

Hypertension management in obstructive hypertrophic cardiomyopathy patients treated with cardiac myosin inhibitors - real world data.

International journal of cardiology·2026
Same journal

Fully quantitative CMR rest perfusion reveals myocardial perfusion abnormality in Kawasaki disease: Association with left ventricular Remodeling.

International journal of cardiology·2026
Same journal

Predicted adherence and ischaemic stroke risk in atrial fibrillation patients initiating oral anticoagulation: A cohort study of the medication adherence score.

International journal of cardiology·2026
Same journal

Severe tricuspid regurgitation is a congestion-driven cardiorenal disease: A longitudinal study defining a right heart failure phenotype.

International journal of cardiology·2026
Same journal

Applicability of ischemic heart disease clinical practice guidelines in low- and middle-income countries.

International journal of cardiology·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Primary cardiac lymphoma.

Carlos E Miguel1, Reinaldo B Bestetti

  • 1Department of Internal Medicine, Hospital de Base, Brazil.

International Journal of Cardiology
|March 16, 2010
PubMed
Summary
This summary is machine-generated.

Primary cardiac lymphoma (PCL) is a rare heart cancer, often diffuse B-cell lymphoma, predominantly affecting immunocompromised individuals. Early diagnosis and novel treatments like immunotherapy offer hope for this aggressive condition.

Related Experiment Videos

Last Updated: Jun 15, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Area of Science:

  • Cardiology
  • Oncology
  • Hematology

Background:

  • Primary cardiac lymphoma (PCL) is an exceptionally rare malignancy.
  • Histologically, most PCL cases present as diffuse B-cell lymphoma.
  • PCL incidence is higher in immunocompromised populations.

Purpose of the Study:

  • To review the clinical presentation, diagnosis, and treatment of primary cardiac lymphoma.
  • To highlight the diagnostic challenges and prognostic factors associated with PCL.
  • To discuss emerging therapeutic strategies for PCL.

Main Methods:

  • Review of existing literature on primary cardiac lymphoma.
  • Analysis of diagnostic modalities including imaging and cytology.
  • Evaluation of treatment outcomes and prognostic indicators.

Main Results:

  • Common clinical manifestations include pericardial effusion, heart failure, and atrioventricular block.
  • Imaging techniques like echocardiography, CT, and MRI aid in diagnosis, but cytologic examination is definitive.
  • Prognosis is generally poor, with a median survival of approximately 7 months.

Conclusions:

  • PCL requires a high index of suspicion, especially in immunocompromised patients.
  • Multimodality imaging and cytologic confirmation are crucial for diagnosis.
  • Emerging treatments such as rituximab immunotherapy and autologous stem cell transplantation show promise for improving outcomes.